bezafibrate has been researched along with D-fructopyranose in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (18.18) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ikeda, S; Kusama, H; Nishiyama, M | 1 |
| Bastow, MD; Durrington, PN; Ishola, M | 1 |
| Harada, Y; Inoue, I; Ishii, J; Itabashi, A; Katayama, S; Negishi, K; Takahashi, K | 1 |
| Hibino, M; Ito, T; Kawakami, K; Matsui, H; Okumura, K; Toki, Y | 1 |
| Richey, JM; Si, X; Webb, RC | 1 |
| Fujioka, Y; Iwasaki, T; Masai, M; Morimoto, S; Ohyanagi, M; Okumura, T; Tsuboi, S; Tsujino, T | 1 |
| Kiniwa, M; Matsuura, N; Ohmori, K; Yamada, H; Yamamoto, A; Yasuda, A | 1 |
| Oron-Herman, M; Rosenthal, T; Sela, BA | 1 |
| Ackerman, Z; Grozovski, M; Link, G; Oron-Herman, M; Pappo, O; Rosenthal, T; Sela, BA | 2 |
| Ackerman, Z; Ben-Ari, Z; Chepurko, Y; Cohen, M; Grossman, E; Hochhauser, E; Leibowitz, A; Schmilovitz-Weiss, H; Yitzhaki, S | 1 |
1 trial(s) available for bezafibrate and D-fructopyranose
| Article | Year |
|---|---|
Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial.
Topics: Bezafibrate; Clinical Trials as Topic; Dietary Carbohydrates; Double-Blind Method; Fenofibrate; Fructose; Humans; Lipoproteins; Male; Propionates; Triglycerides; Uric Acid | 1988 |
10 other study(ies) available for bezafibrate and D-fructopyranose
| Article | Year |
|---|---|
[Pharmacological investigation of bezafibrate, a hypolipidemic agent (1). Effects of bezafibrate on normal and experimental hyperlipidemia in rats].
Topics: Administration, Oral; Animals; Bezafibrate; Cholesterol, Dietary; Depression, Chemical; Fructose; Hyperlipidemias; Male; Polyethylene Glycols; Rats; Triglycerides | 1988 |
Effect of troglitazone (CS-045) and bezafibrate on glucose tolerance, liver glycogen synthase activity, and beta-oxidation in fructose-fed rats.
Topics: Animals; Bezafibrate; Blood Glucose; Body Weight; Chromans; Diet; Drug Tolerance; Fatty Acids, Nonesterified; Fructose; Glucose; Glycogen Synthase; Hypoglycemic Agents; Liver; Male; Mitochondria, Liver; Oxidation-Reduction; Potassium Cyanide; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 1995 |
Improved insulin sensitivity by bezafibrate in rats: relationship to fatty acid composition of skeletal-muscle triglycerides.
Topics: Animals; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Delta-5 Fatty Acid Desaturase; Dietary Carbohydrates; Dietary Fats; Fatty Acid Desaturases; Fatty Acids; Fatty Acids, Nonesterified; Fructose; Insulin; Insulin Resistance; Male; Muscle, Skeletal; Phospholipids; Rats; Rats, Sprague-Dawley; Triglycerides | 1997 |
Bezafibrate, an anti-hypertriglyceridemic drug, attenuates vascular hyperresponsiveness and elevated blood pressure in fructose-induced hypertensive rats.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Animals; Aorta; Bezafibrate; Blood Pressure; Body Weight; Calcium Channel Agonists; Dose-Response Relationship, Drug; Fructose; Hyperinsulinism; Hypertension; Hypertriglyceridemia; Hypolipidemic Agents; In Vitro Techniques; Lipoproteins, VLDL; Male; Rats; Rats, Sprague-Dawley; Vasoconstriction | 1999 |
Troglitazone reduces activity of the Na+/H+ exchanger in fructose-fed borderline hypertensive rats.
Topics: Animals; Bezafibrate; Blood Glucose; Blood Platelets; Blood Pressure; Calcium; Chromans; Diet; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Fructose; Hydrogen-Ion Concentration; Hyperinsulinism; Hypertension; Hypertriglyceridemia; Hypolipidemic Agents; Insulin; Male; Propionates; Rats; Sodium-Hydrogen Exchangers; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone; Vasodilator Agents | 2003 |
Effects of a novel anti-hyperlipidemic agent, S-2E, on blood lipid levels in rats with fructose-induced hypertriglyceridemia.
Topics: Animals; Benzoates; Bezafibrate; Cholesterol; Cholesterol, HDL; Diet; Fructose; Hydroxybenzoate Ethers; Hypertriglyceridemia; Hypolipidemic Agents; Insulin Resistance; Lipid Metabolism; Lipids; Liver; Male; Pyrrolidinones; Rats; Rats, Sprague-Dawley; Triglycerides | 2004 |
Risk reduction therapy for syndrome X: comparison of several treatments.
Topics: Amlodipine; Animals; Antihypertensive Agents; Bezafibrate; Blood Pressure; Body Weight; Captopril; Fructose; Hydrolases; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Metabolic Syndrome; Rats; Rats, Sprague-Dawley; Risk Reduction Behavior; Rosiglitazone; Thiazolidinediones; Triglycerides | 2005 |
Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction.
Topics: Amlodipine; Animals; Antihypertensive Agents; Bezafibrate; Blood Pressure; Captopril; Diet; Fatty Liver; Fructose; Hypolipidemic Agents; Iron; Liver; Male; Rats; Rats, Sprague-Dawley; Triglycerides | 2005 |
Effects of amlodipine, captopril, and bezafibrate on oxidative milieu in rats with fatty liver.
Topics: Amlodipine; Animals; Antihypertensive Agents; Bezafibrate; Captopril; Fatty Liver; Fructose; Hypolipidemic Agents; Male; Metabolic Syndrome; Oxidative Stress; Rats; Rats, Sprague-Dawley | 2008 |
Rosiglitazone and bezafibrate modulate gene expression in a rat model of non-alcoholic fatty liver disease--a historical prospective.
Topics: Animals; Bezafibrate; Disease Models, Animal; Fatty Liver; Fructose; Gene Expression; Hypoglycemic Agents; Hypolipidemic Agents; Liver; Male; Non-alcoholic Fatty Liver Disease; PPAR alpha; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Superoxide Dismutase; Thiazolidinediones | 2013 |